Evidence map›Paper›PMID 42199850›Full record

ReviewFrontiers in chemistry2026

Graph-based deep learning for drug-drug interaction prediction: a systematic review.

Xiaoqing Liu, Xue Yu, Qi Dai

Abstract readReview
In one paragraph

Review in Frontiers in chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xiaoqing LiuCollege of Sciences, Hangzhou Dianzi University, Hangzhou, China.
Xue YuCollege of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, China.
Qi DaiCollege of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Identifying potential drug-drug interactions (DDIs) is crucial for drug development and therapeutic safety, motivating increasing efforts in computational DDI prediction. Although several surveys have summarized recent advances, a systematic review that explicitly organizes existing studies from the perspective of graph-based deep learning paradigms is still lacking. In this work, we present a comprehensive review of graph-based methods for DDI prediction, with a particular focus on three representative technical routes: graph convolutional networks (GCNs), graph attention networks (GATs), and graph contrastive learning (GCL). We review and categorize representative DDI prediction models according to these three paradigms, highlighting their modeling strategies, advantages, and limitations in capturing molecular structures, heterogeneous interactions, and robust representations. We then discuss key challenges and future research directions, emphasizing multi-modal data integration and model interpretability. This review aims to provide a structured overview of the current landscape and to serve as a practical reference for the development of more accurate, robust, and interpretable DDI prediction models.

Indexed as

drug-drug interactiongraph attention networksgraph contrastive learninggraph convolutional networksprediction methods

Identifiers

PMID42199850
PMCPMC13199350

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.